

May 9, 2013



Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/09/13 -- [Titan Pharmaceuticals, Inc.](http://www.titanpharm.com) (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, May 16, 2013. Titan will provide the Company's financial results as of March 31, 2013. The call will be hosted by Sunil Bhonsle, president, Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer, Brian Crowley, vice president of finance and Marc Rubin, M.D., executive chairman.

Highlights of the first quarter financial results will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com. The call can also be accessed by dialing 888-312-3048 Participant code: 7501798 five minutes prior to the start time. A replay of the call will be available on the Company website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals

For information concerning Titan Pharmaceuticals, Inc., please visit the company's website at www.titanpharm.com.

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

For Investors:

Titan Pharmaceuticals, Inc.

Sunil Bhonsle
650-244-4990
President

For Media:

Pure Communications

Dan Budwick

973-271-6085

dan@purecommunicationsinc.com

Source: Titan Pharmaceuticals, Inc.